ADC Therapeutics (NYSE:ADCT – Get Free Report) is expected to be announcing its earnings results before the market opens on ...

Rhumbline Advisers lifted its holdings in ADC Therapeutics SA (NYSE:ADCT – Free Report) by 15.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The ...

ADC Therapeutics SA’s ADCT share price has surged by 11.39%, which has investors questioning if this is right time to sell.

ADC THERAPEUTICS SA -REDH ($ADCT) is expected to release its quarterly earnings data on Thursday, March 13th after market close, per Finnhub. Analysts are expecting ...

Upcoming trends in ADC therapeutics, including their use in autoimmune conditions and the dawn of bispecific designs, are revolutionizing the landscape of targeted therapy. These innovations ...

Stephens raised the firm’s price target on ADC Therapeutics (ADCT) to $8 from $6 and keeps an Overweight rating on the shares. With data from LOTIS-5 and LOTIS-7 using Zylonta as a backbone ...

Do the numbers hold clues to what lies ahead for the stock? ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ...

Myris, formerly known as BioHybrid Solutions, has built on its history in enzyme bioconjugate development to emerge as a new Antibody Drug Conjugate (ADC) therapeutics company focused on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These appointments come at a pivotal time as Ona accelerates the development of its first-in-class ADC therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer ...